In a speech at his first all-hands-on-deck meeting, acting FDA Commissioner Ned Sharpless, MD, vowed to carry through on efforts launched by his predecessor Scott Gottlieb, MD.
Dr. Sharpless said the administration would continue its efforts to curb youth tobacco use and rein in prescription drug costs by increasing competition and advancing its generic drug and biosimilars programs.
"I am not planning any radical changes from what the FDA has been trying to accomplish," Dr. Sharpless said. "I plan to maintain FDA’s current course of action in every area and proceed full speed ahead."
Dr. Sharpless told attendees of the meeting that he will be releasing a more detailed explanation of his public health priorities in the coming weeks.
Dr. Sharpless is the former director of the National Cancer Institute.